These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 8675168)

  • 1. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
    Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
    Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
    Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Balkau B; Eschwège E; Poupon R
    N Engl J Med; 1991 May; 324(22):1548-54. PubMed ID: 1674105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
    Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
    Merli M; Bertasi S; Servi R; Diamanti S; Martino F; De Santis A; Goffredo F; Quattrucci S; Antonelli M; Angelico M
    J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):198-203. PubMed ID: 7815243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice.
    Pelletier G; Roulot D; Davion T; Masliah C; Causse X; Oberti F; Raabe JJ; Van Lemmens C; Labadie H; Serfaty L;
    Hepatology; 2003 Apr; 37(4):887-92. PubMed ID: 12668982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid in the treatment of chronic liver disease.
    Cirillo NW; Zwas FR
    Am J Gastroenterol; 1994 Sep; 89(9):1447-52. PubMed ID: 8079918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?
    Lindor KD; Janes CH; Crippin JS; Jorgensen RA; Dickson ER
    Hepatology; 1995 Feb; 21(2):389-92. PubMed ID: 7843710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement.
    Drzymała-Czyż S; Jończyk-Potoczna K; Lisowska A; Stajgis M; Walkowiak J
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):645-9. PubMed ID: 26882172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.